A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Clinical trial NCT07297329 · RECRUITING
Trial details
- NCT number
- NCT07297329
- Sponsor
- Sinocelltech Ltd.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-29
- Primary completion
- 2027-12-01
- Enrollment
- 292
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.